Gerald A. Beathard

Gerald A. Beathard

Auto-generated profile, based on publicly available information

Gerald A. Beathard

Department of Medicine, University of Texas Medical Branch, Galveston, TX, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2003 in Kidney International
Verified
Journal Article
Closed access
GBGerald A. Beathard
Gerald A. Beathard
PAPerry Arnold
Perry Arnold
JJJerry Jackson
Jerry Jackson
TLTerry Litchfield
Terry Litchfield
PLPhysician Operators Forum Of Rms Lifeline
Physician Operators Forum Of Rms Lifeline

1 May 1999 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
GBGerald A. Beathard
Gerald A. Beathard
: The dominant problem associated with the use of tunneled-cuffed catheters is infection. When this occurs, two issues must be addressed: treatment of the infection and management of the catheter. The purpose of this 2-yr study was to report the results of a prospective observational series in which catheter management was based on the clinical picture presented by the patient. Data were collected on patients with catheter-related bacteremia (CRB) dealt with in one of three ways: (1) minimal symptoms with a normal-appearing tunnel and exit site (exchange over guidewire within 48 h of antibiotic initiation [Xchng group], 49 cases); (2) minimal symptoms but with tunnel or exit site infection (exchange over a guidewire with creation of a new tunnel [Nutunl group], 28 cases); and (3) severe clinical symptoms (catheter removal with delayed replacement after defervescence [Delay group], 37 cases). All cases were treated immediately with empiric antibiotics followed by 3 wk of antibiotic therapy based on culture sensitivities. A cure was defined as a 45-d symptom-free interval after antibiotic therapy was complete. A cure rate total of 87.8% for the Xchng group, 75% for the Nutunl group, and 86.5% for the Delay group was seen for the 114 episodes of CRB. It is concluded that in selected patients, catheter exchange over a guidewire within 48 h of antibiotic initiation followed by 3 wk of specific antibiotic therapy is a viable treatment option. Additionally, replacing the catheter in patients presenting with severe symptoms of sepsis as soon as they have defervesced is a reasonable approach to therapy.

1 May 1999 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
GBGerald A. Beathard
Gerald A. Beathard
SSStephen M. Settle
Stephen M. Settle
MSMarty W. Shields
Marty W. Shields

1 October 2004 in Kidney International
Verified
Journal Article
Closed access
GBGerald A. Beathard
Gerald A. Beathard
TLTerry Litchfield
Terry Litchfield

20 July 2017 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
GBGerald A. Beathard
Gerald A. Beathard
CLCharmaine E. Lok
Charmaine E. Lok
MGMarc H. Glickman
Marc H. Glickman
AAAhmed A. Al-Jaishi
Ahmed A. Al-Jaishi
DBDonna Bednarski
Donna Bednarski
THThomas S. Huber
Thomas S. Huber
This paper is part of the Clinical Trial Endpoints for Dialysis Vascular Access Project of the American Society of Nephrology Kidney Health Initiative. The purpose of this project is to promote research in vascular access by clarifying trial end points which would be best suited to inform decisions in those situations in which supportive clinical data are required. The focus of a portion of the project is directed toward arteriovenous access. There is a potential for interventional studies to be directed toward any of the events that may be associated with an arteriovenous access’ evolution throughout its life cycle, which has been divided into five distinct phases. Each one of these has the potential for relatively unique problems. The first three of these correspond to three distinct stages of arteriovenous access development, each one of which has been characterized by objective direct and/or indirect criteria. These are characterized as: stage 1—patent arteriovenous access, stage 2—physiologically mature arteriovenous access, and stage 3—clinically functional arteriovenous access. Once the requirements of a stage 3—clinically functional arteriovenous access have been met, the fourth phase of its life cycle begins. This is the phase of sustained clinical use from which the arteriovenous access may move back and forth between it and the fifth phase, dysfunction. From this phase of its life cycle, the arteriovenous access requires a maintenance procedure to preserve or restore sustained clinical use. Using these definitions, clinical trial end points appropriate to the various phases that characterize the evolution of the arteriovenous access life cycle have been identified. It is anticipated that by using these definitions and potential end points, clinical trials can be designed that more closely correlate with the goals of the intervention and provide appropriate supportive data for clinical, regulatory, and coverage decisions.

1 November 2008 in Seminars in Dialysis
Verified
Journal Article
Closed access
PDF file
GBGerald A. Beathard
Gerald A. Beathard
AUAris Urbanes
Aris Urbanes